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.Abstract of the Dissertation
Novel Silica Coated Lipid Nanocarriers for Diagnostics and
Therapeutics
by
Mukanth Vaidyanathan
Doctor of Philosophy in Chemical Engineering
University of California San Diego, 2017
Professor Sadik Esener, Chair
While enzymes of non-human origin are attractive for therapeutic and diag-
nostic applications like in cancer, viral infection and brain diseases, their clinical
use has been limited due to the immune response against foreign proteins. These
enzyme can been hidden and incorporated in particles that are capable of harness-
ing ultrasound energy such that focused ultrasound can expose the enzyme to its
substrate. However, the immune evasion and delivery specificity are key challenges
needing to be addressed.
We propose a silica coated enzyme encapsulated lipid nanoparticle (SiLi)
that protects the enzymes encapsulated within its hollow core of the liposome
from immune attack whilst allowing access to their substrates through its porous
secondary silica layer. The accessibility of the substrate to the enzyme is controlled
xvi
through ultrasound.
In this dissertation, The unique fabrication process of the liposome is dis-
cussed whose intergrity can be exploited by the application of ultrasound. The
ability of the secondary coating prevents the proteases to neutralize the enzymes
in SiLi particles whist maintaining structural integrity. The residence time of the
liposomes and SiLi are also evaluated through intramuscular injections at the hind
limbs in vivo. Additionally different methods to fabricate silica on top of the
liposomes are also discussed.
Finally the application of SiLi with different enzymes for therapy and di-
agnosis are also explored. Enzyme based oxidative therapy were investigated to
generate ROS at the site of injection. Glucose oxidase was used to test the ther-
apeutic efficacy in cells as well as tumor xenografts. SiLi loaded with cocktail of
enzymes are fabricated to optically detect small molecules like ACh. ACh is an im-
portant neurotransmitter which play a key role in the manifesting Alzheimer’s and
Parkinson’s pathology. Thereby a nanoparticle optical probe to detect ACh plays
a pivotal role in brain mapping which could provide insights to disease progression
and possible therapeutic targets.
xvii
Chapter 1
Introduction
Enzymes are protein reactors that conduct chemical reaction in the body.
Enzymes are globular proteins that catalyze alone or through the formation of
several complexes. Several enzymes are found in a living body which catalyze
different reactions which are necessary to facilitate, sustain and thrive life on earth.
There are several enzymes which are devoid in humans but present in several other
organisms that we have harvested for our benefits like the zymase which are still
being used to generated alcohol from sugar. However this has led to the discovery
of several enzymes which have been found to have a therapeutic and diagnostic
aspect in human.
Non human enzymes have been employed for the treatment of several dis-
eases especially cancer. Almost all the therapies in the clinic used so far includes
small molecules and radiation. Unfortunately, they lack the tumor specificity and
accompanies with severe side effects which undermines any therapeutic treatments.
Hence there is a need for the treatment techniques with improved specificity and
prolonged sustenance in the body. Enzymes offer this specificity by interfering
with innate immune mechanisms and regulated processes in the body like angio-
genesis, apoptosis. However, most of these promising enzymes are not suitable for
clinical use, since they fail to remain active inside the body without aggravating
the immune response which results in poor bio availability. Thus foreign enzyme
based therapies and diagnostics require an effective delivery platform that can al-
low stealth operation whilst preventing any access of antibody or serum proteases
1
2to the enzyme encapsulated. The delivery method must be performed at low cost
and complexity without compromising the enzyme activity.
The most commonly used delivery platform without compromising the en-
zyme activity is with the use of nanoparticles. Several nanoparticles organic and
inorganic have been employed to release the drug or proteins at site of interest.
However, certain enzymes when exposed to the substrate which are ubiquitous in
the body might undermine the therapeutic efficacy of enzyme based therapies like
in oxidation therapy (The addition of enzyme to generate ROS in the presence
of substrate leads to systemic toxicity). In order to prevent systemic toxicity by
localizing the effect of these therapies to the site of interest and to achieve target-
specific release, the next inevitable step is for remote-triggered activated release.
Instead of depending on the biological local environment of the target tissue, re-
lease would be reliant on an independent external trigger. One of the strategies
used effectively in the clinic is the use of ultrasound. Ultrasound is desirable trig-
ger because there is no risk of exposure to ionizing radiation present and offers
area-specific penetration without being invasive in the body.
This dissertation elucidates a novel nanoparticle platform, Silica coated en-
zyme loaded Cationic Liposomes (SiLi). The enzyme encapsulated through the
emulsion process remain suspended in the hollow core remain active whilst being
protected through the secondary silica layer. Chapter 2 explains the synthesis and
fabrication of these Silica coated enzyme loaded Cationic Liposomes (SiLi), efficient
protection from antibody access and neutralization, protection from proteolysis,
stability with and without the application of ultrasound in vivo and "activation"
of the enzyme activity upon application of the ultrasound.
Chapter 3 discusses potential applications of SiLi with therapeutic enzymes,
including Glucose Oxidase (GluOx) and Choline Oxidase (ChOx) for various types
of cancer through oxidation therapy.These enzymes have proven efficacy in vitro
but fail to make it to clinic because of systemic generation of toxicity. However
this chapter explains the possible use of GluSiLi.
Chapter 4 discusses potential diagnostic application using multiple enzymes
with different size for detecting neurotransmitters. These enzymes are successful
in optical detection of neurotransmitter in vitro but suffer the same fate as other
3enzymes because of the innate immunity generated against these foreign enzymes.
Chapter 5 explains the ATP detection nanoparticle mechanism using lu-
ciferase. The luciferase was loaded in Synthetic Hollow Enzyme loaded silica nano
spheres (SHELS). These were designed to detect ATP in tumor sites and in pericel-
lular cavity of the neurons. The synthesis and fabrication of SHELS are explained
along with the activity retention of the enzyme upon exposure to proteases. The
effect of different surface coating was explored for effective ATP detection. Lastly
the luminescence was captured in SHELS through high speed camera.
The dissertation concludes by examining the future potential applications of
SiLi for macromolecule delivery.
Chapter 2
Silica Coated Enzyme
Encapsulated Cationic Liposomes
2.1 Liposome
The name liposome is derived from greek works: "Lipos" meaning fat and
"soma" meaning body. It is a tiny vesicle made out of the same material as a cell
membrane, phospholipids [1]. Under normal conditions, the vesicles are spherical
and contain more than one lamellae that are composed of amphiphiles[2][3]. In
nature, liposomes are formed by phospholipids which form stable bi-layer mem-
branes in which the hydrophobic part of the amphiphiles forms the interior of the
bilayer and the hydrophillic part (head group) is in contact with the aqueous phase.
There are several other components to a stable liposome, phospho lipids like phos-
phatidylcholines provide the backbone and structure to lipids, Cholesterol alters
the mechanical properties of the lipid bilayers [4] and the anionic dicetylphosphate
(3 dihexadecylphosphate) or the cationic stearylamine or DOTAP (1,2-dioleoyl-
3-trimethylammonium-propane) with the aim of preventing vesicular fusion[5].To
prevent rapid clearance from the blood, the lipid-polymer derivative of polyethy-
lene glycol (PEG) are used to synthesize liposomes[6]. The interior of the vesicle
is an aqueous core which is of the same chemical composition of the protein or
drug being encapsulated. In fact, they can contain a wide variety of hydropho-
bic diagnostic and therapeutic payloads (See figure 2.1). Thus providing a larger
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5Figure 2.1: Schematic representation of a small monodispersed liposome eluci-
dating the versatility of liposomes by incorporating various compounds either by
encapsulation or by surface attachment of the lipid membrane [7]
encapsulation efficiency per particle and also protecting the encapsulated payload
from metabolic process and immune clearance[8] [9]. Liposomes are available in
many different sizes and shapes. In case of a bilayer structure encapsulating a
payload,is called a liposome, a monolayer structure is called a miCeLle while a
multiple concentric bi-layers is called a large lamellar vesicles [10]. The size of li-
posomes vary from 50-1000 nm in diameter which serves as an convenient delivery
tool.
Because of their biocompatibility, biodegradability, low toxicity and multi
functionality to encapsulate both hydrophillic and hydropholic payloads and ease
in manufacturing has lead to its use in vaccines like Inflexal V for influenza [11],
chemotherapy and synthesis of anti-cancer drugs like Doxil [12],anti bacterial[13]
and anti fungal treatments (Abelcet, Amphotec [14]), protein delivery like insulin
[15].The critical factors for successful formulation of liposomes are their colloidal
and chemical stability of the lipid bilayer. Unfortunately, Vesicular aggregation,
fusion and creaming are the major concerns for the stability of the liposomes which
could lead to the increase in size and change in charge which could limit the applica-
tion of liposomes. It also suffers from physical instability during manufacturing and
6storage. Phospholipids are sensitive to acidic or basic hydrolysis and unsaturated
phospholipids are susceptible to oxidative degradation which makes it unsuitable
for oral delivery[16]. Apart from oxidative degradation, chemical degradation and
hydrolysis of the ester bonds linking the fatty acids (Cholesterol) to the glycerol
backbone could lead to performance failure and peroxidation of unsaturated acyl
chains [17][18][19].
2.1.1 Silica Coated Liposomes
Extensive research have been conducted to improve the stability of lipo-
somes either by addition of lipid-PEG conjugate [20], polymers [21], polyelec-
trolyte layer-layer assembly[22] and colloidosomes[23]. However, the chemically
assembling Silica layer onto the external surface of the liposomes have been very
successful because it retains the fundamental properties of the free liposomes [24].
Silica coated liposomes act as nonporous spheres for larger molecules like protein
but extremely permeable for smaller molecules like glucose, ATP, vitamins. Silica
nanoparticles can be prepared from various process: noncovalently bound orag-
nic substrates (surfactants, lipids, polymers), cavitation, eletrodeposition, spray
drying, super critical fluid technology, self assembly and sol-gel polymerization
[25][26] [27] [28].Due to the inert nature of Silica, it has been used for enhanced
oral absorption of hydrophobic drugs like CeLecoxib and indomethacin [29].
2.1.2 Active Targeting of the Liposomes
The stability of the liposomes to retain their payload on circulation have
been exploited to deliver drugs to disease tissues. Apart from passive targeting
through EPR, triggering the release of the payload upon reaching the target site
would vastly improve the therapeutic efficacy with minimal side effects. Two main
kinds of triggers have been studied, one is remote trigger through external source
like the heat, ultrasound, light and magnetism and second, endogenous triggers
that are mainly prevalent in the target site like through enzyme and pH.
To release the loaded payloads in the liposomes, one could change the tem-
perature to below the glass transition temperature of the lipids which leads to
7aberrations in the lipid bi-layer packing, thereby creating transient pores [30], the
use of pulses of strong electric field to break the membrane apart [31], the use of
magnetic field to induced 2-4oC change in temperature leading to the phase tran-
sition temperature of the lipids used [32], visible light which could lead to photo
degradation of lipids or a photo sensitive molecule attached to the cholesterol [33],
pH [34] and use of ultrasound (US) to acoustically disrupt the bi-layer through
cavitation [35][36][37].
Ultrasound is widely used in medicine for many years mostly as a diagnostic
tool in gynaecology, obstetrics and cardiology[38]. Ultrasound can be categorized
as either low- or high-intensity. The High Intensity Ultrasound (HiFU) ( 1MHz)
are usually focused at a point of interest to increase the temperature to 60oC
which causes ablation[39] while Low Frequency Ultra Sound (LFUS) (20kHz to
1MHz) are used to imaging and improve the permeability of biological barriers
like the skin[40][41]. Ultrasounds contrast agent like air, gas and low diffusive
gases like perfluoro carbons was developed to enhanced the reflected signal from
the site of interest. These contrast agents were called as echo enhancers. Due
to low toxicty of the liposomes and the tendency of the lipids to expand under
low frequency ultrasound let to the usage of the liposome as carriers of the echo
enhancers. Thereby, Exposing the liposomes to low-frequency ultrasound causes
the formation of transient pores on the packing arrangement of the lipid bi-layer
within the membrane resulting in an increase in the permeability of the liposome
and thereby releasing the drug.[42][43].
Recently there has been growing interest in combining ultrasound and lipo-
some for triggered release of anti cancer drugs that have low release kinetics like
the cisplatin[41][44][45]. The advantages foreseen to encapsulating this drug within
a liposome was to achieve reduced toxicity and drug resistence. Since cisplatin and
doxorubicin in doxil are highly small neoplastic compounds, The liposome should
maintain enough structural integrity to retain the drugs and remain in circula-
tion so that it accumulates in the cancer tumors and release the payload upon
ultrasound exposure. Hence the lipid formulation plays a very vital role in this
combined treatment [46][47]. However with larger payloads like enzymes, the re-
leased enzymes upon application of ultrasound would be counter productive as the
8Figure 2.2: A schematic representation of the formation of transient pores in the li-
posome membrane by ultrasound. The transient pores may occur due to formation
of small gas nuclei in the hydrophobic region of the lipid bilayer under the effect of
an ultrasonic field. The pores may be either hydrophobic (A) or hydrophilic (B) in
nature, and tend to reseal after short periods of time. The formation of transient
pores may free membrane fragments from the liposomes, which will then form into
smaller lipid aggregates. [41]
released enzyme would generate heightened immune response as the enzymes are
of foreign source. Hence liposomes loaded with enzymes require access to the sub-
strate in the serum but remain protected from antibody neutralization and hence
require additional secondary coating like Silica, whose structure and function re-
mains unaffected by the ultrasound[48].
This chapter would elucidate the combination therapy of liposomes coated
with secondary layer of hydrolyzed Silica and Ultrasound. The application of ul-
trasound triggers the breakage of the lipids and hence making the particle porous
to substrate. The enzyme remain active upon ultrasound with little to no immune
response. We specifically show the activation of the enzyme and its sustained activ-
ity upon treatment with the serine proteases. Subsequently section also compares
the bio availability of the Silica coated liposomes to the cationic liposomes through
the encapsulation of BSA conjugated fluorophore. We have also demonstrated that
upon subsequent exposure of the ultrasound doesn’t affect the bio availability of
the Silica coated liposomes in vivo.
92.2 Materials
L-Alpha-Phosphotidylcholine derived from egg yolk (Egg-PC) of 25 mg/ml
stock solution in chloroform, Cholesterol powder, 1,2-Distearoyl-sn-glycero-3- phos-
pho ethanol amine Poly-ethylene Glycol MW5000 (DPSE-PEG) powder and 1,2-
Dioleoyl-3-trimethyl ammonium-propanol (DOTAP) of 10mg/ml stock solution
in chloroform were purchased from Avanti polar lipids, USA. Diethyl ether and
Tetramethyl orthoSiLcate (TMOS) were purchased from Sigma Aldrich, MO, USA.
Phosphate buffer saline was purchased from Life Technologues, USA. Nucleopore
Track-Etch Whatman filters 13mm (800 nm, 400nm and 200 nm) used in the
extrusion process and 19mm Nucleopore Track-Etch Whatman 30 nm pore size fil-
ter were purchased from EMD Millipore, Darmstadl, DE. The magnetic dialyzing
cartridge: fast SpinDialyzer was purchased from Harvard Apparatus, Holliston,
MA. Lyophilized betalactamase (BLA) from Enterobacter cloacae was purchased
from Sigma Aldrich, St Louis, MO, USA. Bovine serum albumin conjugated with
alexafluor 680 (BSA-AF) was purchased from Thermo Fisher Scientific, Waltham,
MA. Nitrocefin was purchased from Millipore MD, Darmstadl, DE and used to test
the enzyme kinetic of BLA. Phosphate Buffer Saline (PBS) was purchased from
Hyclone Laboratories Inc,Logan, UT. All the chemicals were used as received.
2.3 Methods
2.3.1 Synthesis of Enzyme Loaded Cationic Lipid nanopar-
ticles (liposomes) (CeLi)
The cholesterol stock solution was prepared with 38.7 mg of lyophilized pow-
der of cholesterol in 1 ml of Chloroform. The DSPE-PEG stock solution was
prepared by mixing 50mg of DSPE -PEG in 1 ml of chloroform. All the lipid stock
solutions were prepared in chloroform and stored in −20oC freezer. Egg-PC and
DOTAP was used as received. Liposomes were synthesized through a modified
version of the reverse phase evaporation technique developed by Papahadjopoulos
[49]. It consists of three step process.
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Solution A: 295 ul of 25mg/ml of Egg-PC, 40 ul of 38.7 mg/ml of Cholesterol,
50ul of 10mg/ml of DOTAP were mixed in a glass vial and the chloroform was
evaporated using Buchi Rotavapor R-300 at 100 rpm at 25o C for 20 minutes to
form a thin lipid film. Then 1ml of diethyl ether was added to re-suspend the
lipids in ether.
Solution B: 40 ul of 38.7mg/ml of cholesterol, 50 ul of 25mg/ml of DOTAP
and 60 ul of DSPE-PEG stock solutions were mixed in 0.5 ml eppendorf tube. The
chloroform was evaporated under a gentle stream of nitrogen while vortexing the
open tube. 100ul of the PBS was added while making empty liposomes or 100 ul of
100mg/ml of BLA was added to make enzyme loaded liposomes. All the enzymes
were hydrolyzed individually using PBS. The lipid-payload solution was vortexed
thoroughly for 30 secs until all the lipids are constituted in the solution.
Solution C: 60 ul of DSPE-PEG stock solution was evaporated under gentle
nitrogen stream while vortexing in a 1 ml eppendorf tube. Then 1 ml of PBS was
mixed until all the lipids are evenly mixed in the solution.
Solution B was added dropwise in the glass vial containing solution A under
vortex. Then solution was allowed to vortex in high speed for 1 minute. This emul-
sion is homogenized to ensure proper mixing using the Power Gen 125 homogenizer
from Fisher Scientific for 2 minutes. The ether in the stabilized emulsion is evap-
orated under vacuum using Buchi Rotavapor at 100rpm at 30oC for 25 minutes.
This produces a sol-gel like precipitate. The sol-gel mixture is then hydrated by
addition solution C dropwise under gentle vortex. Gentle stream of nitrogen was
used to create vortex to break apart large chunks and then vortexed for 30 sec-
onds. This solution was placed in vacuum for 45 minutes under a water bath at
30oC. The liposomes are then extruded three times using a syringe extruder with
800nm, 400nm and 200nm filters respectively. The extrusion process was slow and
steady to ensure homogeneous solutions of liposomes are formed. To remove ex-
cess enzyme and lipids, the solution was dialyzed at 160 rpm at room temperature
overnight using the fast SpinDialyzer with 19mm whatman filters with pore size of
30nm. Schematic representation on the synthesis of CeLi is shown in the figure2.3.
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Figure 2.3: A schematic representation of the formation of liposomes through
reverse phase evaporation.(A) Solution A (B) Addition of solution B to Solution
A (C) Water in oil emulsion is formed to form stable micelles (D) Gel formation
upon solvent evaporation (E) Dissolution of the gel with solution C
2.3.2 Synthesis of Silica Coated Enzyme Loaded Liposomes
(SiLi)
The CeLi are used as a template to precipitate Silica using sol-gel method as
shown below in figure2.4. 50 µl of the liposomes is diluted with 1 ml of PBS. 2 µl
of TMOS is added drop wise over vortex to this solution and mixed for 4 hours at
3200 rpm in a shaker at room temperature to form Silica coated Liposomes (SiLi).
To terminate the hydrolysis of TMOS, the SiLi solution was washed three times
in PBS using a centrifuge at 3000 rpm for 15 minutes at 25oC.
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Figure 2.4: A silica formation process using PBS and TMOS
Figure 2.5: A schematic representation of the formation of silica on CeLi
2.3.3 Synthesis of Calcium Phosphate (CaP) Coated En-
zyme Loaded Liposomes (CaL)
50µl of CeLi is diluted with 1ml of 0.1X PBS. 100ul of 1mM of calcium
chloride (CaCl2) is added dropwise under vortex to diluted CeLi mixture. The
mixture was mixed for 30 mins to 1 hour at 3200 rpm at room temperature. To
terminate the deposition, the solution was washed three times in PBS using a
centrifuge at 3000rpm for 15 minutes at 4oC.
2.3.4 Characterization of the CeLi, SiLi and CaL
The size and surface charge of the liposomes were characterized using Ze-
tasizer Nano from Malvern Instruments, Malvern, UK. The size was also char-
acterized using electron microscope images using the Helios NanoLab DualBeam
from FEI. The particle count was analyzed using ViewSizer 3000 from Manta, San
Diego, CA. The activity of the enzyme was optically detected using Spark M20
from Tecan, Mannerdorf, SUI.
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2.3.5 Nitrocefin Assay for the Measurement of BLA activ-
ity
For the colorimetric determination of penicillinase activity, 100µl enzyme
solutions were transferred onto a 96-well microtiter plate. 25µl nitrocefin working
solution was added to each well. 5 milligram nitrocefin was dissolved in 500µl
DMSO, and 9.5 mL 1X PBS was added to obtain the working solution. Absorbance
at 486 nm was measured at 37oC using Infinite 200 PRO Plate reader and Spark
M20 Tecan (Switzerland) .
2.3.6 Measurement of in vivo Activity
Athymic, nude mice were purchased from the Jackson Laboratories (Stock
number: 002019). Mice were housed in high-efficiency particulate air (HEPA) cages
in a specific-pathogen free (SPF) facility at OHSU. Mice were fed a diet of PicoLab
Mouse Diet 20 (LabDiet, 5058) ad libitum and started one week prior to imaging.
10 week old male nude mice were given a single 100uL intramuscular injection
of either SiLi, CeLi and Free BSA-AlexaFlur in the both high leg muscle. Mice
were imaged for fluorescence (excitation wavelength = 680nm, emission wavelength
= 710nm, exposure = 0.2sec) after correcting for background fluorescence using
the IVIS Lumina XRMS Series III (PerkinElmer). All experiments performed
were approved by the Institutional Animal Care and Use Committee (IACUC) at
OHSU.
2.3.7 Measurement of Activation of the CeLi and SiLi us-
ing Ultrasound
For in vitro ultrasound activation, The BLA encapsulated in the liposomes
and SiLi were treated with 50KHz bench top sonicator. The samples were treated
with pulsed ultrasound at 2 second on and 1 second off intervals for 2 minutes at
40% amplitude under ice bath to prevent overheating of the sample and therefore
leading to enzyme denaturation.
For in vivo ultrasound activation, SiLi, CeLi and unencapsulated BSA-Alexa
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Flur were injected on the left and right hind leg muscle. The left hind leg was
exposed to ultrasound at 25-55MHz for 30 seconds and the region of injection was
scanned at 100frames/second using (write this equipment down ). The fluorescence
was measured using IVIS Lumina XRMS Series III (PerkinElmer) as described
above.
2.4 Results
The proteins (BLA and BSA-AF) are encapsulated during the formation of
water-oil emulsion during the formation of the liposome nanoparticles. The size of
the nanoparticles are of atmost importance to ensure higher circulation or retention
time in the body. The size of the nanoparticles synthesized was measured before
and after dialysis as well after coating it with Silica. The figure2.6 shows the size
distribution of CeLi (before and after dialysis) and SiLi particle to around 215 nm
irrespective of the coating.
Figure 2.6: The size of the non dialyzed CeLi (Blue), Dialyzed CeLi (Orange) and
SiLi (Grey) were all measured at the same dilution in 1X PBS with 12 runs for
each measurement using disposable clear size cuvettes
The CeLi particles are cationic and with an average charge of around +15mV.
This cationic charge is due to the presence of DOTAP in on the lipid bilayer. Since
Silica (from TMOS) is anionic, it would preferentially deposit on the cationic CeLi
particles thereby changing the charge of the particles to shift from +15mV to
-36mV as shown in 2.7.
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Figure 2.7: The change in the surface charge between non dialyzed CeLi (Blue),
dialyzed CeLi (Orange) and SiLi (Grey) were all measured at the same dilution in
DI water with 12 runs for each measurement using disposable clear zeta cuvettes
For characterization of the nanoparticles, BLA was encapsulated in the CeLi
and SiLi.BLA (43kDa) is a member of the family of beta-lactamases that catalyze
the hydrolysis of the beta-lactum ring [50][51]. BLA was selected for the char-
acterization of Silica coated liposome (SiLi) because sensitive chromogenic and
fluorgenic assays were available[52]. The encapsulation efficiency of the nanoparti-
cles was determined by incubating all the samples with 0.1mg/ml of proteinase K
(28.9kDa) overnight at 37oC while mixing. Proteinase K is a broad spectrum serine
protease that cleaves at the peptide bond adjacent to the carboxyl group of the
aliphatic and aromatic alpha amine groups [53][54][55]. The activity of the enzyme
which is encapsulated by the particles can be determined using nitrocefin assay.
Nitrocefin being a cephalospoin contain beta-lactum ring which is susceptible to
BLA mediated hydrolysis .Once hydrolysed, nitrocefin rapidly changes color from
yellow to red which can be measured as an increase in absorbance at 486nm using
UV-Vis spectrometer. Figure2.8 demonstrates the protection of the enzymes which
are encapsulated within the SiLi particles upon sustained exposure to proteinase
K.
The purpose of DOTAP while forming the emulsion was to provide a cationic
charge to the CeLi particles thereby providing an oppositely charged template to
drive preferential silica deposition. Hence, Silica,an FDA approved inorganic mate-
rial could be electrostatically and chemically deposited on the CeLi surface. Silica
can be precipitated on any surface especially nanoparticles using many different
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Figure 2.8: Activity plots of unencapsulated and encapsulated BLA in SiLi with
and without incubation with proteinase-K for 24 hours at 37oC in 1X PBS in
bench top shaker. 0.5 mg/ml of nitrocefin in 1mM phosphate buffer was added to
measure the increase in absorbance at 486 nm.
substrates [56]. APTMS, TMOS and Silicic acid (highly reactive and acidified form
of TMOS) was the choice of precursor for the formation of synthetic silica shell on
the CeLi particles along with CaP. Figure2.9 shows all the different surface coating
techniques were employed on BLA loaded CeLi and tested for BLA activity after
encapsulation and also after treatment with proteinase K.
Sonication of the CeLi and SiLi particles were performed for 2 minutes at 40%
amplitude at 2 seconds on and 1 seconds off using 500W 20kHz sonicator attached
to a cone to prevent sample contamination from the insertion of the probe. As
seen from figure 2.10 the sonicated and non sonicated samples were incubated with
the PK. The BLA-CeLi particles showed an 700% increase in the activity of the
sonication while BLA-SiLi showed an 800% increase in activity. However, upon
incubation of the samples with proteases, BLA-CeLi showed 97% loss in activity
and upon sustained sonication did not revive the activity of the BLA. Whereas,
the BLA-SiLi retained 97% of the enzyme activity and upon sustained exposure
for an additional 48 hours with proteases did not lower the enzyme activity.
100µl of BLA-SiLi, BLA-CeLi and Free BSA-AF were injected intramuscu-
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Figure 2.9: Activity plots of BLA with different surface coating with and without
the treatment with PK. The PK was treated for 24 hours at 37oC in 1X PBS in
benchtop shaker. 0.5 mg/ml of nitrocefin in 1mM phosphate buffer was added to
measure the increase in absorbance at 486 nm.
larly on either side of the hind limbs of the mice. 55MHz of US was applied on the
left hind limb for 30 seconds and images were captured through IVIS. Figure2.11
and Figure2.12 shows the comparison between different particles with the free. The
free BSA and BSA-CeLi lost its fluorescence within 1 day and 4 day respectively
while the BSA-SiLi lasted for about 7 days before disappearing. Dye-IR was used
to tag the lipids in the liposomes and were found to be at the site of injection even
after 9 day post injection.
2.5 Discussion
Strong anionic shift in the surface of the CeLi particles is a clear indication
of the addition of silica on the surface of CeLi. As seen in figure2.7 there is a
strong shift toward the negative paradigm. This shift is due to the anionic nature
of silica. The size of the particles was confirmed with SEM as its nearly impossible
to image liposome using the standard SEM as it would collapse under vacuum.
Figure2.8 indicates that secondary silica layer in SiLi provides a physical bar-
rier for against proteases and antibody. Upon sustained exposure to proteases, the
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Figure 2.10: Activity plots of the BLA-CeLi and BLA-SiLi particles upon incuba-
tion with protease for 24 and 48 hours in 37oC. PK samples: Particles incubated
with PK prior to sonication. PK sonicate: Particles that were sonicated 24 hours
after the addition of PK. Sonicate PK: Particles were sonicated prior to the ad-
dition of PK and incubated for 24 hours.Sonicate PK Sonicate*: Particles were
sonicated, incubated with PK for 24 hours. Then sonicated again and incubated
with PK for an additional 24 hours
free enzyme would be denatured as there isn’t any barrier protecting the enzyme
from proteases while the enzyme in SiLi retains it activity indicating complete
protection from the proteases whilst having access to the substrate. Silica can be
deposited on a template through many precursors while we have tried to use three
different precursors. From Figure, TMOS seems to form a much more compact
Silica structure while being non porous to the proteases and hence retaining the
most activity after incubation with PK.
CeLi generally tend to form a tight barrier thereby limiting the interaction
of the payload with the environment. Hence, It has been proven through many
studies that this tight layer can be disrupted through sonication (see figure2.10).
Since the payload in our study is an enzyme, losing the payload upon the appli-
cation of ultrasound would be counterproductive to our objective. Therefore, the
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addition of secondary barrier in SiLi not only protects the enzymes from the en-
vironment but also retains the enzymes inside the particles upon sonication. This
ability to retain the enzymes after sonication is absolutely necessary in vivo to pre-
vent heightened immune response. Figure2.10 clearly elucidates the retention and
protection capabilities of SiLi particles. The addition of PK mimics the proteases
present in the body in vitro.
To envision the usage of any fabricated nanoparticle, high priority is given
to animal experiments. Similarly with CeLi and SiLi, SiLi particles are retained
in the muscle for about 7 days post injection. However, the lipids labelled with
Dye-IR is clearly visible at the site of injection even after the loss of the BSA-AF
fluorescences which is the payload encapsulated inside SiLi. This indicates that SiLi
particles clearly can be used for IM injection while the CeLi are really poor choice
for IM injection as they tend to behave as free BSA-AF. Due to weak structural
integrity of the CeLi particles, the addition of Si improves the retention time of
the payload. It also clearly indicates that the addition of US doesnt necessarily
affect the retention time of the SiLi.
However, the retention time can be improved further by the usage of ad-
ditional lipids like sphingolipids, phosphosphingolipids, 1,2-dioleoyl-sn-glycero-3-
phospho ethanol amine (DOPE) etc. These lipids are much more rigid and can
prevent collapse of liposomes which triggers the release of payload. The secondary
layer of silica is however too thin as addition of more TMOS just leads to formation
of free silica particles rather coating a thicker layer on the particles.
2.6 Conclusion
Here we have demonstrated a process for consistent production of SiLi con-
taining stabilized cationic liposomes. Though the overall structure is new, the
outer Silica layer is amenable to standard functionalization and modifications well
documented in the literature. These particles can be selectively insonified with
ultrasound. This allows for both spatial and temporal control over activation of
the enzymes by triggering perturbations within the lipid bi layer making these
particles promising for in vivo studies.
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The addition of ultrasound improves the enzymatic activity by providing
lower diffusive resistance of the substrate into the particles. Certain application
may require intravenous injection which may require addition fabrication of the
Silica layer to prevent uptake in liver and spleen.
Inspite of the tight binding of the lipids in the liposomes, there are still
leakage of the substrate into the particles. The use of sphingolipids in the CeLi
may provide additional resistance thereby making the access of substrate to the
enzyme even more harder.
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Figure 2.11: Demonstration of BSA-AlexaFLuor688 fluorescence in free and BSA-
CeLi upon intra muscular injection
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Figure 2.12: Demonstration of BSA-AlexaFLuor688 fluorescence in BSA-SiLi upon
intra muscular injection at different time points. Inset is Dye-IR fluorescence image
to label the lipids to form the liposomes
Chapter 3
Therapeutic Applications of SiLi
3.1 Glucose Oxidase encapsulated SiLi (Glu-SiLi)
for in vivo generation of Hydrogen Peroxide
Reactive oxygen species (ROS) are small molecules of oxygen derived species,
including both oxygen radicals (anions like O.−2 , OH− etc) and non oxygen rad-
icals (H2O2), that are highly reactive due to the presence of unpaired electrons.
In aerobic life forms, molecular oxygen is ubiquitous and hence acts a perfect
electron acceptor of the free radicals to form oxygen free radicals. ROS plays
an important role in many cellular developments, growth, apoptosis, mutagenesis,
drug metabolism, immunogenicity against foreign bodies and development of can-
cer[57][58].ROS are predominantly generated during metabolism through various
enzymes. However, in a mammalian cell, the ROS is involved in ATP synthe-
sis by aerobic metabolism in mitochondria. However, electrons that escape the
mitochondria react with oxygen to form of O.−2 which can be converted to H2O2
by superoxide dismutatase[59]. The H2O2 can readily cross the cell membrane
through lipid peroxidation and lead to DNA damage [57]causing apoptosis. Ad-
ditionally the free radical oxygens may also react with nitrogen to form reactive
nitrogen species (NO,.NO2).Under pathological conditions, excessive generation of
these ROS (also known as oxidative stress) can initiate lethal reactions that initi-
ates and progresses lethal diseases like the cardiovascular diseases, cancer, inflam-
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mation, ischemia-reperfusion injury, viral pathogenesis, hypertension, formation
of drug or microbe resistance etc.These lethal reactions involves the oxidation of
the proteins involved cellular integrity and survival [60][61]. To overcome ROS,
normal healthy cells have evolved and maintained a series of anti-oxidative defense
mechanisms to minimize the exposure of these dangerous byproducts occurring
naturally during cell metabolism[62]. The defense mechanism includes a cock-
tail of enzymes like super oxide dismutase, catalase and glutathione peroxide and
free radical scavenging compounds like heme oxygenase-1, glutathione, tocopherol,
ascorbate.Hence the balance of ROS and anti-oxidative defense level is critical for
cellular growth, survival and sustenance as shown in the figure3.1.
Figure 3.1: Schematic representation illustrating homeostasis of ROS in the body
and the drawbacks due to excess generation of ROS and suppression of defense
mechanisms
However in cancer it has been proven that the enzymes responsible for an-
tioxidative defense are none to minimal[63][64][65][66]. This means that ROS is not
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only responsible for promotion and progression of cancer mutagenesis[67] through
the activation of redox-responsive signalling like epidermal growth factor, tyrosine
phosphorylation and protein kinease C[68] but also increases its vulnerability thus
providing a unique anti tumor functionality. This unique antitumor effect via gen-
eration of ROS[69] selectively only in tumors is known as oxidative therapy [70][71].
Hence this non linear dependence of cancer on ROS provides an unqiue opportu-
nity for the treatment of tumors. Surprisingly, many chemotherapy agents like
doxorubicin, vinblastine, cisplatin and inostamycin exhibit anti tumor therapeu-
tic effect by generation of ROS[72].However, ROS like H2O2 are highly unstable
and extremely hydrophillic so the desired therapeutic effect of H2O2 cannot be
manifested until it is generated continuously. As H2O2 used alone is ineffective in
causing the desired level of necrosis in tumors[73][74]. This could be perhaps due to
catalase and other anti-oxidative defense systems which could clear the ROS from
the region. Thus sustained production of H2O2 is an effective approach to achieve
antitumor effect. There are several mechanisms through which oxidative therapy
can be used as an antitumor therapy. The use of enzymes which generate ROS
by metabolizing common substrate available in the system to H2O2 like glucose
oxidase (GluOx), ChOx, xanthine oxidase (XO) etc. In direct method to generate
ROS in a specific location would be through enzyme-prodrug therapy, where HRP
can be localized the tumors and a prodrug, in this instance Indole-3-Acetic Acid
(IAA) can be supplied systemically. The prodrug is diffused through blood to the
site of HRP localization, where HRP converts IAA to H2O2 thereby generating
an oxidative environment. Hence only a controlled generation of H2O2 is achieved
through this method, thereby reducing the possible systemic side effects[75]. Most
of the enzymes used in oxidative therapy are from non human source. This would
lead to generation high immune response and rapid clearence from the blood. In
order to prevent the neutralization and maintain the foreign enzyme activity, cova-
lent conjugation with PEG to synthesize enzyme PEG conjugates. PEG by itself
improves the solubility in both organic and aqueous solvents, improved circulation
half life in vivo, none to minimal toxicity and immunogenicity and easy excretion.
PEG-protein/enzyme and PEG- drug conjugates have been employed clinically for
the treatment of various forms of cancers which high efficacy. PEG provides a rich
26
pharmocokinetic advantages to any particle, proteins or enzymes. However there
are a few downside to this approach, the addition of peg could lead to altering the
enzyme activity due to non specific covalent binding of the PEG to the protein.
Recent studies have also suggested the generation of immune resistance against
PEG which could compromise the therapeutic efficacy of bio molecules conjugated
with PEG.
3.1.1 Enzymes Assisted Oxidative Therapy
As mentioned before several enzymes have been used as a source to gener-
ate H2O2 in situ in the body. Most of the studies has been performed through
intra tumor injection to the tumor of the enzyme and PEG-enzymes. Almost all
of the enzymes used in oxidative therapy are flavo proteins[76] [77][78]. Earlier
experiments were conducted with XO, DAO and GluOx. XO is a iron containing
enzyme that oxidizes hypoxathine to generate ROS through a two step process3.2.
Even though, XO is an excellent candidate for ROS generation but native XO have
known to have a high affinity to endothelial cells lining the blood vessels. This
high affinity could be detrimental to the treatment in sight.
Figure 3.2: Schematic representation of XO reaction: Hypoxanthine is converted
to xanthine in the XO while Xanthine is catalyzed to uric acid also in presence of
XO while both the catalysis steps generate ROS
H2O2 generated from XO could cause oxidative damage to the blood vessels
and endogenous nitric oxide (NO) could rapidly react with H2O2 thereby resulting
in increasing the possibility of elevating the blood pressure. NO is known for its
vascular dilation properties and hence lowering NO would lead necrosis or tissue
degeneration through insufficient circulation[79][80].
DAO is another flavo-protein that have been studied for its anti-tumor prop-
erties by ROS generation3.3. DAO catalyses stereo selective amino acids with the
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exception of D-aspartic acid and D-glutamic acid to H2O2 and its corresponding
-keto acids[70][81].
Figure 3.3: Schematic representation of DAO reaction: D amino acids is catalysed
to α amino acid to generate ammonia and ROS
Addition of exogenous d-amino acids is necessary because of the insufficient of
amino acids levels in the system. DAO when injected in vivo has lower circulation
time as they can be excreted through urine. This is because the molecular size of
DAO is 39KDa while the threshold for renal purification and excretion is 50KDa.
To overcome this drawback people have used PEG conjugation on DAO to not
only improve the circulation time but also provide protection against the immune
system[59][82].
Glucose Oxidase (GluOx) is flavo protein belonging to the oxido reductase
class of enzymes. GluOx catalysis the conversion of D-glucose utilizing oxygen
to gluconic acid and simulatenous generating toxic H2O2[83][76]. This dimeric
enzyme has been used commercially as glucose sensors in diabetes. GluOx have
also been used in toothpaste, skin care products and in food and deverage indus-
tries as well. However, the use of GluOx as an effective therapeutic agent isnt
as heavily studied as compared to other applications. Due to the generation of
H2O2 by utilizing oxygen and glucose, which are ubiquitous in the body makes
GluOx a excellent candidate for oxidative therapy in tumors. The by product,
D-gluconolactone which is generated by GluOx is also metabolically inert and on
the contrary provides therapeutic relief especially on skin[84][85].
Abundance of glucose and oxygen in the body aids in generation of ROS by
GluOX but it would also generate systemic toxicity when GluOx are administered
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intravenously due to the generation of H2O2 instantly and it would also cause a
rapid immune clearance thereby reducing the available enzyme[86]. The latter can
be prevented by the conjugating GluOx with PEG while its the former that poses a
serious problem. One way to partially localize the generation of cytotoxic H2O2 is
to inject intratumorally the PEG-GluOx conjugates. PEG-GluOx is highly soluble
in aqueous solutions due to PEG, have high probability to leak out of the tumor
vasculature and causing systemic toxicity. Hence there is to activate the GluOx
only at the site of interest and retain the activtiy at the site of injection.
GluOx primarily generates H2O2 (and importantly no other ROS). Since
GluOx substrates (glucose and oxygen) are abundant in all biological compart-
ments and since its product (d-gluconolactone) is metabolically inert, the GOX-
system can be considered an ideal model for physiological H2O2 release.
The main drawback for this kind of therapy is the site specific generation
of ROS, tumors in the case of cancer. This can be achieved through multitude of
techniques.
3.2 Materials
Lyophilized powder of Glucose Oxidase (GluOx) from Aspergillus niger was
purchased from Sigma Aldrich,St Louis,MO. Amplex Red Glucose/Glucose Oxi-
dase assay kit was purchased from Invitrogen, Carlsbad,CA. Vybrant MTT Cell
Proliferation Assay kit was purchased from ThermoFisher Scientific, Waltham,MA.
5 mg of MTT was aliquotted into 10 ml of DMEM and stored in 4oC.
3.3 Synthesis of Glu-SiLi
Glucose oxidase (GluOx) loaded CeLi (Glu-CeLi) was synthesized with the
method described in chapter 3 using 100mg/ml of glucose oxidase in PBS as the
stock solution. Silica coated liposome encapsulating GluOX (Glu-SiLi) was syn-
thesized by adding 1:5 ratio of APTMS: TMOS per 50µl of Glu-CeLi. The reaction
was conducted under vortex for 2 hours and then centrifuged and re suspended
three times in PBS at 3200 rcf at room temperature.
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3.3.1 Characterization of Glucose Oxidase
0.5µl of the sample were mixed in 1ml of PBS to estimate the size range for
both the particles while the charge was measured in DI water instead of PBS. The
size of the SiLi particles was further confirmed using SEM.
3.3.2 Glucose oxidase kinetics and activity study
GluOx activity was characterized using colorimetric amplex red assay. The
assay was conducted for 30 minutes at 37oC with 100µM of amplex red reagent,
0.2U/ml of HRP and 100mM of glucose. The fluorescence of resorufin was mea-
sured at 545nm and emission at 590nm. The absorbance was also measured at
560nm. The standard curve for GluOX was conducted using the standard enzyme
issued in the assay kit and serial diluted to 10mU to 0.1mU. Kinetic cycle was
conducted to measure the absorbance and fluorescence. The standard curve was
plotted with the absolute values measured after 30 mins of incubation with the
enzyme concentration.
3.3.3 Toxicity Study of Glu-SiLi with MTT Assay
Glu-CeLi and Glu-SiLi enzyme encapsulation was determined using the stan-
dard curve of the free GluOx. The activity of the enzymes were matched before the
addition to the cells. HeLa (ATCC CCL-2) cells was used to test GluOX toxicity
and these cells were sub cultured at least 4 times prior to the study. 5000 cells/
well were plated and incubated 24 hours prior to any treatment. The treatments
were only studied upon 60-70% con fluency each well. All the samples including
the free gluOX was serial diluted and incubated with cells for 3 hours and 24 hours.
Before the addition of the MTT reagent, the media was removed and replaced with
the media containing 0.2mM MTT. The cells were incubated at 37oC incubator
for 3 hours before the addition of 50µl of DMSO to determine the absorbance at
540nm. The lethal concentration was determined at 50% cell viability for each
particles (free, Glu-CEl and Glu-SiLi).
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3.3.4 In vivo Therapeutic Efficacy
Male athymic (Ncr nu/nu) nude mice, approximately 4-6 weeks old on arrival,
were obtained from Jax Laboratory Animal CO. Animals were housed in laminar
air-flow cabinets under special pathogen-free conditions and fed with autoclaved
standard chow and water at 26-28oC and humidity at 40%-60%. xenografts were
initiated by subcutaneous injection of 5x1010 A549 cells into the right and left
flanks of the nude mice.
Experimental treatments were started when tumors had grown to an average
of 60mm3 in volume. Mice were randomly divided into three groups: group 1
(control, n=2) was injected with just PBS, group 2 (n=2) unencapsulated GluOx
while group 3(n=2) was injected with GluOX particle. Prior to the injection all
the samples were match with the activity of Glu-SiLi particles. The tumor size
was measure for 15 days and upon sustained injections with 200U of Glu-SiLi at
day 5 and day 12. The mice was sacrificed after the duration of the experiment
and sections were stained for hemotoxylin and eosin to determine necrosis.
3.4 Results
The size of Glu-CeLi and Glu-SiLi are 250 nm and 300 nm respectively
however the surface charge of the Glu-CeLi was measured to be around -12mV
compared to the BLA-CeLi of +15mV. The addition of silica coating on the Glu-
CeLi using APTMS and TMOS was measured to be -26mV.
Standard curve of the GluOx was performed and used to calculate the ac-
tivity of the GluOx encapsulated in the CeLi and SiLi particles. This was always
performed prior to the treatment with cells to determine the lethal concentration
for 24 hours and 3 hours. Figure 3.4 shows the percentage viability of 5000 HeLa
cells per well. Figure 3.4b shows almost a linear trend in the cell viability with
increase enzyme activity. Lethal concentration at 50% cell viability for 3 hours was
found to be around 1.5-2 U/ml for all the samples however the lethal concentration
at 50% cell viability could be verified for cells incubated with GluOX samples for
24 hours as shown in figure3.4a. Loading efficiency in both Glu-CeLi and Glu-SiLi
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was found to be same and there was not much loss in the activity due to the silica
coating.
100µl of 14U of GluOX was injected in intratumorally (IT) at day 0 followed by
(a) 24 hour incubation (b) 3 hour incubation
Figure 3.4: Percentage viability of cells upon incubation of free GluOX, Glu-CeLi
and Glu-SiLi for 24 hours and 3 hours respectively
100µl injection of 220U of Glu-SiLi particles at day 5 and day 11 for the period of
experiment of 14 days after which the mice were sacrificed. As from the figure the
tumor size didnt not show any change between the tumors injected with Glu-SiLi
particles and PBS. The tumors size was to found to be growing regardless of the
treatment.
However to test the efficacy of the hydrogen peroxide generation in vivo
20U and 200U of free GluOx was injected subcutaneously. the mouse injected
with 200U of GluOx subcutaneously died in less than 24 hours while the mouse
injected with 20U subcutaneous appear to be losing about 2g of weight in less
than 5 days post injection. However, the mouse injected with 20U of GluOX
intravenously also died in less than 24 hours. Heat inactivated GluOx was also
injected intravenously and subcutaneously to determine that cause of death of
mice was due to the generation in hyrodgen peroxide generation due to the GluOx
and not due to the endo toxins found in commercially available enzymes. The
mouse injected with heat inactivated GluOx appear to be normal even after 14
days. The tumors were harvested and histology slides were prepared to check for
apoptosis (see figure3.6) or necrosis markers (see figure3.7). The tumors treated
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Figure 3.5: Percent change in the tumor volume measured between the mice treated
IT with Glu-SiLi (blue) and untreated-PBS (red)
with Glu-SiLi was found to be showing signs of necrosis compared to untreated
tumors.
TUNNEL stain was performed to check for apoptosis markers but there
wasn’t any significant difference between the treated and untreated tumors as seen
in the figure3.7.
3.5 Discussion
The size of Glu-CeLi compared very much to the other CeLi formulations
loaded with BSA and BLA, thereby the size of the GluOx had little to no effect on
the size of the CeLi formed. However, The surface charge is highly influences by
the charge of the protein being encapsulated. BSA and BLA CeLi were cationic
with +12mV because the charge of BSA and BLA was found to be less than -5mV
but the GluOX measured to be -18mV which might have led for the anionic surface
charge in spite of the addition of DOTAP. It is highly likely that the most of the
inner lipid bilayer must be lined with DOTAP due to preferential electrostatic
33
Figure 3.6: Histology slide of the tumors of GluOx treated and control (untreated).
The circle represents the area of necrosis in the region of section
attraction to GluOX.
GluOX forces the cells to apoptosis by generating excessive ROS consistently.
Figure3.4 shows MTT assay incubated with cells in plate for 24 hours and 3 hours
at different GluOX concentrations. It is apparent that even at lower GluOX con-
centration more than 50% of the cells undergo apoptosis. This could be due to
consistent ROS generation while consuming glucose. Since its a static system as
no extra glucose supplement were provided to the cells due the treatment. This
cell death could be due to ROS and glucose but the in vivo the level of glucose
is maintained thereby the only cause of cell death would be due to ROS produc-
tion. However the cells incubated only 3 hours with Glu-SiLi, there appears to
be linear trend in cell death with the concentration of GluOx loaded as there isnt
suffifient time to generate ROS hence only the maximum doseage generated 50%
cell viability.
Figure3.4a and figure3.6 shows that in vivo the tumors undergo necrosis due
to ROS generation and not just due to glucose depletion. As seen in figure3.6, the
xenografts undergo necrosis but the size of the tumor doesnt under any change.
The tumor volume doesnt undergo much change even after treatment because the
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Figure 3.7: Histology slide of the tumors of GluOx treated and control (untreated).
TUNNEL staining was performed to stain the area of apoptosis on the slide section
tumor volume is too huge and the since the injection is mostly at the center of the
tumor, the ROS has been able to dissipate deep into the tumor periphery. Figure3.7
shows that there is no apoptosis marker in tumor sections as the apoptosis occurs
only 24 hours after injection with the ROS. This is consistent that ROS causes the
tumor to undergo necrosis through apoptosis.
3.6 Conclusion
We have demonstrated the use of Glu-SiLi to generate ROS for the treatment
of tumor. The efficacy is of H2O2 generation to trigger cell death is prominent at
the site of injection but fails to interact with cells in the periphery. The amount
of cell death corresponds to the amount of GluOx loaded in SiLi but even at lower
GluOx loading there is visible cell damage.
The ability of Glu-SiLi to kill cells is only through the generation of H2O2
and not through depletion of glucose as the un-encapsulated enzyme through IV
generated systemic shock through high ROS production leading to mice’s death in
less than 2 hours.
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Chapter 4
Diagnostic Application of SiLi
4.1 Acetylcholine (ACh)
Acetylcholine (ACh) is an organic chemical that is found in brain and body
of humans and animals. Its structure is composed of acetyl ester and choline.
Predominantly ACh is found in the human body as a neurotransmitter and also
acts as a neuromodulator. The parts of the body that is affected by the release
of this neurotransmitter are referred to as cholinergic. In central nervous system
(CNS), cholinergic projections from the basal forebrain to the cerebral cortex and
hippocampus aid in cognitive functions[87]. In addition to cognitive functions,
ACh also aids in arousal, increasing attention, memory and motivation. Primarily
in the Peripheral nervous system (PNS)[88], this chemical is released by motor
neurons in order to activate the muscles. ACh is also the major neurotransmitter
in the autonomic nervous system (ANS)[89], as an internal neurotransmitter for
the sympathetic nervous system and as the final product released by the parasym-
pathetic nervous system. However, the specific functions of each ACh-releasing
neuronal population are largely unknown.
In the cerebral cortex, ACh is released from long axons projecting from the
neurons in the basal forebrain with contributions from many cholinergic interneu-
rons [90]. Like the cerebral cortex, hippocampus and its neighboring regions are
innervated with extrinsic cholinergic inputs from medial septal nuclei, which is re-
sponsible for the theta waves in an EEG and also by intrinsic cholinergic interneu-
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rons[91][92]. ACh can activate both excitatory nicotine acetylcholine receptors
(nACHRs) and muscarinic acetylcholine receptors (mACHRs) in these systems.
These receptors are responsible for regulating the post synaptic release of neuro-
transmitters from the presynaptic cell which alters synaptic plasticity and post
synaptic cellular excitability[93][94].
ACh is synthesized in the presynaptic terminals in cholinergic neurons using
choline (Ch) and Acetyl CoEnzyme A (ACoE-A)(see figure4.1). This reaction is
catalyzed by Choline Acetyl tranferase (ChAT)[95]. The ChAT derived from the
brain has a KD of 1mM for Ch while 1µM for ACoE-A. Inhibitors of ChAT do
not lower ACh synthesis in vivo; this could be because of lack of sufficient local
concentration of the inhibitor but it also suggests that this step is not the rate-
limiting in the synthesis of ACh.Ch is present in the blood and the concentration is
about 10µM. There are preferentially two choline uptake transporters(ChT): One
is the "low affinity" ChUT with a kM of 10-100µM which are found in all the cells
and tissues in the body while the second uptake system is the "high affinity" sodium
ChT which are present only in the cholinergic neurons with a KM of 1-5µM[96].
Since the plasma concentration is enough to saturate the high affinity ChTs, ACh
synthesis would be sustained even under high demand neuronal activity. However
the Ch concentration inside the presynaptic terminals is not expected to change
by increasing the Ch concentration in plasma. Studies have been conducted to
specifically block the high affinity ChT at nerve endings using inhibitors like 3-
Hemicholinium, to study the effect of ACh synthesis. It has been proven that ACh
synthesis has been altered or lowered by the use of ChUT inhibitors. Hence, the
rate of ACh synthesis is dependent on the rate of Ch transport into the presynaptic
terminals[97][98][99].
4.2 Acetylcholinesterase (AChE)
AChE is a serine hydrolase. The active site of AChE (figure4.2a contains a
triad of amino acids: serine, histidine and glutamate (an acid residue), a structure
similar to that of trypsin[101]. AChEs are found in the synapse between nerve
cells and muscle cells. It catalyzes the hydrolysis of ACh to Ch and acetate.
38
Figure 4.1: Schematic illustration of ACh synthesis in a cholinergic presynaptic
nerve terminal and synapse.The choline uptake transporter (ChT) at the mem-
brane of nerve ending transports Ch into the cell, where it is catalyzed by ChAT
to generate ACh using ACoE-A in the vicinity of the synaptic vesicle. The vesic-
ular acetylcholine transporter (VAChT) concentrates ACh in the vesicle. ChT is
also found on the vesicle but in a functionally inactive state. Upon nerve stimula-
tion, ACh-containing vesicles fuse with the membrane and release their contents.
The fusion of the membrane results in more ChT being exposed to the synaptic
gap, where it becomes active. ACh is hydrolyzed to Ch and acetate in the pres-
ence of acetylcholinesterase (AChE). The Ch is then bound to ChT which is then
transported back to the nerve ending[100]
The breakdown of ACh at the synpases allows the Ch to be re-uptaken by the
synaptic terminal for further processing Ch to ACh[102]. This is important in
terminating the nerve transmission at the synaptic junctions. AChe is one of
the fastest enzymes but the exact mechanism is still unclear. Interestingly, the
ACh released in the synaptic junctions are enough to saturate all the cholinergic
receptors and AChEs present in the synapes. 80% of ACh binds to the receptors
in the receiving cell while only 20% binds to the AChEs[103]. This is because of
two reasons: First, the rate at which the ACh binds to the receptors is higher
than that rate at which the AChE can hydrolyze the ACh. Second, the rate at
which ACh is released from the receptor is slower than the hydrolysis by AChE
and hence, there is always a low ACh concentration at the synaptic cleft at any
time after the the transmission and this also excludes any non specific binding of
39
(a) Structural features of AChE as found
through X-Ray crystallography which de-
picts the active site to be below the gorge
like structure of AChE
(b) 3D model of AChE. Blue regions repre-
sents the anionic sites while red region rep-
resents the catalytic side found deep inside
the folded structure
Figure 4.2: Illustration of AChE structure derived from the Torpedo californica
ACh to any other cells or receptors[104][105]
AChE has a multitude of roles which are not readily accepted. Studies have
suggested that regulated expression of AChE has been found during early embryo-
genesis[106], synpatogenesis [107]and neuritogenesis [108] but the role of AChE
during these early stages of embryogenesis is still being studied. AChE have also
been found in regions of the brain with little to no inputs from cholinergic neu-
rons like cerebellum, globus pallidus, hypothalamus and non nervous tissues like
the testis[109], haematopoetic [110] , osteogenic and various neoplatic cells and
in erythrocytes[111][112]. AChE is extensively prominent in tissues that are in-
nervated with cholinergic neurons like the CNS, ANS and PNS primarily at the
neuromusclar junctions[113].
4.2.1 Importance of ACh Detection
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by
the deposition of β-amyloid (Aβ) plaque in the extracellular space, formation of
neurofibrillary tangles in neurons, and extensive neuronal loss[114]. The neurode-
generation results in loss of memory, mood and behavior changes and difficulty in
speaking, swallowing and walking in severe cases [115][116]. Although the precise
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cause of AD remains unclear and is in fact most likely of multiple etiologies, aggre-
gated Aβ-peptides constitute a prime neurotoxic component of senile plaques in
the brains of AD patients. In addition to genetic influences, environmental factors
appear to play a role in AD pathogenesis, with evidence that environmental factors
such as stress and exercise can influence the formation of plaques and tangles [117].
Although other neurotransmitters were known to be involved in learning and mem-
ory performance, the functions of cholinergic system in learning and memory were
of predominant interest in this aspect[118]. Cholinergic loss is the most severe and
consistent biochemical change in AD patients[119]. ACh which acts as the neuro-
transmitter in cholinergic systems were found to be significantly decreased in AD
patients which is a result of decrease in concentration of the ChAT compared to age
normalized patients [120].Several research have concluded that there is a selective
loss in a specific gobular form of enzymatically active membrane bound AChE in
cortical and subcortical regions in AD patients [121][122].The regional distribution
of these deficits is significantly correlated with histopathological features of the dis-
ease as the membrane bound form of AChE is predominately found in cholinergic
neurons[123]. AD is not the only disease of the brain that is affected by the loss in
cholinergic systems. The cholinergic neurons of the cerebral cortex and hippocam-
pus have been described to undergo moderate degenerative changes during aging,
thereby resulting in cholinergic hypofunction that is related to the gradual memory
loss with aging. Cholinergic atrophy and cell loss in normal brain due to aging
is not complemented by reductions in the neural growth factors (NGF) levels as
studies have shown that NGF provides tropic support to cholinergic neurons which
promote neuronal survival, increases sprouting of cholinergic neurons both in vitro
and in vivo[124] [125][126][127]. Although Parkinson disease (PD) is a progressive
disorder of neurons that affect movements due to denervation of dopaminergic neu-
rons, recent studied have shown the effects of this progressive disease in non motor
features such as dementia. This elucidates the multi-system neuron denervation
which extends beyond dopaminergic systems[128]. Cognitive impairment in PD is
manifested in patients mainly by attention and executive dysfunctions which can
be attributed to the significant loss in cholinergic neurons in the forebrain. Infact
the loss in cholinergic functions have been found to be greater in forebrain in PD
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than in AD[129][130]. Hence with the necessity for the detection of various neuro-
transmitters and outlining the map of the brain plays a very crutical role in drug
discovery and targets for treating several diseases which manifest due to not just
one neurological pathway mutation but multi-system mutation. We chose ACh
because of its role in not just in cognitive and motor development and regulation
but also the source for many delibitating conditions like paralysis[131], dementia,
AD, PD, schrizophenia [132] and addiction[133].
4.2.2 Current Detection Techniques
Imaging has played a variety of roles in the study of AD, PD, mild cognitive
impairment, Schizophrenia and dementia over the past couple of decades. Ini-
tially, computed tomography (CT) and then magnetic resonance imaging (MRI)
were used to diagnose dementia and several other brain anomalies. Recently dif-
ferent varieties of imaging modalities like Structural Magnetic Resonance Imaging
(MRI), Functional magnetic resonance imaging (fMRI) and Positron emission to-
mography (PET) have been employed in the clinic to study and characterize the
neuronal metabolic fluctuations using chemical compounds known as tracers.The
signals obtained with PET and fMRI are based on changes in blood flow, oxy-
gen consumption and glucose utilization that correspond to a precise way to the
cellular activity of the brain, including astrocytes and neurons. Structural MRI
with different field strengths (1-3T) has been used to achieve better resolution and
improving the signal to noise ratio to clearly differentiate between vascular struc-
tures, white and gray matter. However with higher power(7-9T), resolution can
be improved of several 100’s of microns[134][135]. This has enabled quantification
of cortical volume with high precision and hence aids in the monitoring of dis-
ease progression (refer figure4.3). MRI includes several other imaging techniques
like the Diffusive tensor imaging MRI(DTI-MRI), resting state MRI, Real time
MRI, Diffusion MRI,Magnetic resonance angiography, T1rho MRI, Neuromelanin
imaging, Fluid attenuated inversion recovery (FLAIR) etc.
Studies have shown that with novel rapid data acquisition programs and the
confinement of contrast agents within the vascular compartments has led to mea-
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Figure 4.3: Comparison of structural MRIs of Hippocampus between alzheimers
patient (a) and normal adult(b)
surements of changes in blood brain volume using MRI technique. This led to the
demonstration of functional mapping of the brain along with its precise anatom-
ical features using MRI. This type of MRI is called functional MRI (fMRI)[136].
fMRI was also used to evaluate the magnetic susceptibility of oxygenated and de-
oxygenated blood due to change in the oxygen and glucose concentrations in brain.
This led to the development of Blood-oxygen-level dependent fMRI (BOLD-fMRI)
which is the most widely used imaging tool in brain[137]. Apart from BOLD, there
are several other fMRI techniques like arterial spin labelling (ASL), cerebral blood
flow, cerebral blood volume.
PET derives its name and its fundamental properties from a group of ra-
dionuclides which measure the metabolic activities in the body. The radionuclides
emits positron which generate gamma rays which are then captures by the de-
tectors. Currently, 3 dimensional images are generated with PET along with CT
scan. PET scans are currently employed to image cancer tumors, pharmacokinet-
ics, cardio vascular system and the neuronal activities. Most widely used imaging
modalities for the brain activity especially in characterising the progression on AD
is the amyloid PET. In short, 18F-labelled amyloid PET bind specifically to amy-
loid aggregates specifically but to tau proteins or α-synuclein which are usually
the underlying causes for the progression of neural disorders.
This strong affinity of the tracers provides positive or negative amyloid load
in the brain but cannot provide an accurate quantification of amyloid aggregates.
Hence, it has to be used in coherent with fMRI and DTI-MRI to provide in a
precise information on both functional and metabolic anomalies. Inspite of the
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Figure 4.4: AmyloidPET scans of Alzheimers patient and Healthy patient
drawbacks of amyloid PET, it still can be classify patients who are at a higher risk
of progressing to AD from MCI[138].
Since brain is highly heterogenous with both complex structural and func-
tional regions at various sites in the brain, the ability for an imaging technique
to fully resolve these complexities is in part dependent on its spatial and tempo-
ral resolution. There isn’t one imaging modality that can serve all purposes as
each one have their own unique strengths and weaknesses[139]. The challenge for
the future will be to correlate the imaging biomarkers efficiently to facilitate diag-
nosis, disease staging, and, development of effective disease-modifying therapies.
Therefore, it is desirable to develop nanoscale devices that can (i) probe the con-
centration of ACh with high resolution to understand and characterize in space
and time of ACh production and/or depletion in response to a stimulus, and (ii)
modulate non invasively at desired locations and time the ACh in the brain to carry
on behavioral longitudinal tests. Unfortunately, presently, there are no techniques
available to track and sense the rapidly changing concentration of neurotransmit-
ters in response to specific stimulus and to modulate the concentrations with high
spatiotemporal specificity. In addition, very few methods exist to non-invasively
and spatiotemporally modulate neurotransmitter concentrations[140][141][142].
However, In this chapter, we explain the use of enzyme for optical detection
of ACh. There are several commercially available kits that can be used in vitro to
detect ACh but cannot function with similar capabilities in vivo without causing
adverse immune reaction. The use of three different enzymes (AChE, ChOx and
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HRP) in SiLi is elucidated in detail below (see figure4.5).
Figure 4.5: Flow chart of the cascading reactions using AChE, ChOx and HRP to
detect ACh optically from commercially available kits
4.3 Materials
L-α-Phosphotidylcholine derived from egg yolk (Egg-PC) of 25mg/ml stock
solution in chloroform, Cholesterol powder, 1,2-Distearoyl-sn-glycero-3- phospho
ethanol amine Poly-ethylene Glycol MW5000 (DPSE - PEG) powder and 1,2-
Dioleoyl -3- trimethyl ammonium-propanol (DOTAP) of 10mg/ml stock solution
in chloroform were purchased from Avanti polar lipids, USA. Diethyl ether and
Tetramethyl orthosilicate (TMOS) were purchased from Sigma Aldrich, MO, USA.
Phosphate buffer saline was purchased from Life Technologues, USA. Nucleopore
Track-Etch Whatman filters 13mm (800 nm, 400nm and 200 nm) used in the ex-
trusion process and 19mm Nucleopore Track-Etch Whatman 30 nm pore size filter
were purchased from EMD Millipore, Darmstadl, DE. The magnetic dialyzing car-
tridge, fast SpinDialyzer was purchased from Harvard Apparatus, Holliston, MA.
Lyophilized Acetylcholinesterase (AChE) from Electrophorus electricus (electric
eel), Choline Oxidase (ChOx) from Alcaligenes sp.,Peroxidase from Horseradish
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(HRP) were purchased from Sigma Aldrich, St Louis, MO, USA. Fluorometric
Amplex Red assay kit to detect acetylcholine /acetylcholinesterase was purchased
from ThermoFisher Scientific, USA. Phosphate Buffer Saline (PBS) was purchased
from Hyclone Laboratories Inc,Logan, UT.
4.4 Preparation of AChE Loaded Liposomes
The cholesterol stock solution was prepared with 38.7 mg of lyophilized pow-
der of cholesterol in 1 ml of Chloroform. The DSPE-PEG stock solution was
prepared by mixing 50mg of DSPE -PEG in 1 ml of chloroform. All the lipid stock
solutions were prepared in chloroform and stored in −20oC freezer. Egg-PC and
DOTAP was used as received. Liposomes were synthesized through a modified
version of the reverse phase evaporation technique developed by Papahadjopoulos
[49]. It consists of three step process.
Solution A: 295 ul of 25 mg/ml of Egg-PC, 50 ul of 38.7 mg/ml of Cholesterol,
50ul of 10mg/ml of DOTAP were mixed in a glass vial and the chloroform was
evaporated using Buchi Rotavapor R-300 at 100 rpm at 25o C for 20 minutes to
form a thin lipid film. Then 1ml of diethyl ether was added to re-suspend the
lipids in ether.
Solution B: 40 ul of 38.7mg/ml of cholesterol, 50 ul of 25mg/ml of DOTAP
and 60 ul of DSPE-PEG stock solutions were mixed in 0.5 ml eppendorf tube. The
chloroform was evaporated under a gentle stream of nitrogen while vortexing the
open tube. 100ul of the PBS was added while making empty liposomes or 100
ul of enzyme cocktail was added to make enzyme loaded liposomes. The enzyme
cocktail consisted of 33.3 ul of 50mg/ml of AChE, 33.3 ul of 50mg/ml of ChOx
and 33.3 ul of HRP. All the enzymes were hydrolyzed individually using PBS. The
lipid-payload solution was vortexed thoroughly for 30 secs until all the lipids are
constituted in the solution.
Solution C: 60 ul of DSPE-PEG stock solution was evaporated under gentle
nitrogen stream while vortexing in a 1 ml eppendorf tube. Then 1 ml of PBS was
mixed until all the lipids are evenly mixed in the solution.
Solution B was added dropwise in the glass vial containing solution A un-
46
der vortex. Then solution was allowed to vortex in high speed for 1 minute. This
emulsion is homogenized to ensure proper mixing using the Power Gen 125 homog-
enizer from Fisher Scientific for 2 minutes. The ether in the stabilized emulsion
is evaporated under vacuum using Buchi Rotavapor at 100rpm at 30oC for 25
minutes.
This produces a sol-gel like precipitate. The sol-gel mixture is then hydrated
by addition solution C dropwise under gentle vortex. If needed, Gentle stream of
nitrogen was used to create vortex to break apart large chunks and then vortexed
for 30 seconds. This solution was placed in vacuum for 45 minutes under a water
bath at 30oC. The liposomes are then extruded three times using a syringe extruder
with 800nm, 400nm and 200nm filters respectively. The extrusion process was slow
and steady to ensure homogeneous solutions of liposomes are formed. To remove
excess enzyme and lipids, the solution was dialyzed at 160 rpm at room tempera-
ture overnight using the fast SpinDialyzer with 19mm whatman filters with pore
size of 30nm.
4.4.1 Synthesis of Silica coated AChE/ChOx/HRP Loaded
Liposomes(ACH-SiLi)
These cationic liposomes are used as a template to precipitate silica. 500µl
of the liposomes is diluted with 1.5 ml of PBS. 20 ul of TMOS is added dropwise
over vortex to this solution and mixed for 4 hours at 3200 rpm in a shaker at room
temperature to form Silica coated Liposomes (SiLi). To terminate the hydrolysis
of TMOS, the SiLi solution was washed three times in PBS using a centrifuge at
3200 rcf for 15 minutes at 25oC.
4.4.2 Characterization of the ACH-SiLi
The size and surface charge of the liposomes were characterized using Zeta-
sizer Nano fromMalvern Instruments,Malvern, UK. The size was also characterized
using electron microscope images using the Helios NanoLab DualBeam from FEI.
The particle count was analyzed using ViewSizer 3000 from Manta, San Diego, CA.
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The activity of the enzyme was optically detected using Spark M20 from Tecan,
Mannerdorf, SUI.
4.4.3 Characterization of AChE Activity using Amplex Red
Assay kit
AChE activity was characterized using colorimetric amplex red assay. The
assay was conducted for 60 minutes at 37oC with 400µM of amplex red reagent,
2U/ml of HRP, 0.2 U/mL choline oxidase and 100 ÂţM acetylcholine. The fluores-
cence of resorufin was measured at 545nm and emission at 590nm. The absorbance
was also measured at 560nm.
The standard curve for AChE was conducted using the standard enzyme issued
in the assay kit and serial diluted to 100U to 0.1U. Kinetic cycle was conducted
to measure the change in absorbance and fluorescence. The standard curve was
plotted with the absolute values measured after 60 mins of incubation with the
enzyme concentration and also with the slope of enzyme activity with time.
4.5 Results
The size of AChE-CeLi and AChE-SiLi were found to be similar to BLA-
CeLi and SiLi. Inspite of the higher size of the enzyme, AChE loading did not
compromise the surface charge of the CeLi particles unlike the glucose oxidase
loaded CeLi. As to simulate the breaking of lipids in the liposomes to allow access
of the substrate to the AChE, Two different surface coating was employed on
AChE-CeLi. From the figure 4.6, calcium phosphate coated CeLi (CaPLi) and
SiLi particles loaded with AChe did increase the AChe activity by almost 150%
compared to the CeLi particles. However, Sustained exposure to PK did lower
neutralize the AChE encapsulated in the CeLi particles but retained most of the
activity in CaPLi and SiLi particles.
For the detection of the ACh in vivo there requires a cascade of enzymes for this
process as mentioned before. To mildly simulate in vivo condition, SiLi particles
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Figure 4.6: AChE activity in three different particles before and after PK treatment
and with and without sonication
were synthesized containing all the 3 enzymes (AChE, ChOx and HRP) and SiLi
containing individual enzymes separately. All the SiLi particles were tested with
only ACh and also with ACh and Ch. Experimental results as seen in figure 4.7
showed that free enzymes (AChE, ChOx and HRP) provided the quickest and
fastest detection of ACh in the solution. However, the particles containing all
the 3 enzymes (AChE, ChOx and HRP) in one SiLi particle showed faster and
better detection compared to 1 enzyme encapsulated in individual SiLi particles.
The addition of Ch to solution however improved the detectability of 1 enzyme
SiLi particles but it did not provide the detection signal as compared to other 3
enzymes in one single SiLi particles.
4.6 Discussion
AChE is a large molecule enzyme which could hinder the surface charge or
the size of the CeLi and SiLi particles. However the size and charge remains the
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Figure 4.7: Kinetics of Free, three enzyme (AChE, ChOx and HRP) in one SiLi
particle and 3 SiLi particles each containing a different enzyme of the cascade at
1µM of ACh and 1µM of Ch
same as of the BLA-CeLi and SiLi particles which shows that the enzyme shows
little to no affect on the encapsulating nanoparticle. Proteases are found to be
effective on AChE and hence was used a surrogate for the immune system in vitro.
Different coating was conducted on the CeLi particles in order to show the versa-
tility on surface conjugation and modification of CeLi particles without affecting
the payload activity. The coatings not only maintained the enzyme activity, it
also provides a physical barrier to AChE from the proteases to prevent degrada-
tion and neutralization. As seen from the figure 4.6, two FDA approved inorganic
compounds were used and both were effective in maintain the enzyme activity
even after sonication. Due to the application of these particles in detecting neu-
rotransmitters, CaP coating was employed to mimic hydroxyapaptite present in
our body to trigger least immune reaction in the brain. This would be extremely
important as the end product from this cascading enzyme leads to the production
of hydrogen peroxide which is highly toxic in any part of the body mainly the
neurons. The addition of silica and CaP coating also provides the an avenue for
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external activation of these particles through ultrasound. However, Silica proved
to be a better coating material compared to CaP because of its ability to minimize
enxyme -substrate reaction before the application of the ultrasound.
Since majority of the reactions in nanoparticles requires the substrates to
diffuse through the particles. Any addition surface coating would provide diffusion
resistance to ACh and Ch to diffuse into the particle. These nanoscale barrier
does cause a significant delay in detection the ACh. Also our body is a concoction
of various proteins, amino acids and vitamins. Since our process involves the
conversion of ACh to hydrogen peroxide which reacts with HRP and amplex red
or luminol to generate an optical readout, there are many situations that can
interfere with the fluorescence. The second enzyme in the cascading process in
ChOx whose substrate in Ch which is formed by the degradation of ACh through
AChE. Ch is also consumed through diet and is used in many different processes
in a human body. The presence of Ch in the brain especially drastically increases
the chances of cross talk. In order to determine the effect of choline to the optical
detection, we purged some Ch along with ACh to observe any change or shift in
the peak.
As seen from the figure 4.7, 4 different combination of SiLi particles were
synthesized. One SiLi particle containing all the 3 enzymes of the cascading process
and three other SiLi containing individual enzymes of the cascading in each SiLi
particle respectively. According to the hypothesis, more diffusion barrier the more
time it takes to detect ACh and Ch while less physical barrier, the quicker it takes to
detect the particles. As seen in the figure 4.7, free which represents unencapsulated
enzymes of the cascade (AChE, ChOx and HRP) provide the quickest detectiong
because of the ease inaccessibility of the substrates for each enzyme. 3 enzymes
in SiLi particles provides the second quickest detection time, as the only barrier
between the ACh and the three enzymes in the nanoparticles is just the silica
coating of one single SiLi particle as all the three enzymes are present in one SiLi
particle. The addition of Ch to ACh doesnt not change the detection time and
remains the same which could be attributed to the fact that the time required for
ACh to diffuse into the particle and Ch particles are the same since both these
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particles are small molecules. However, when there are 3 different SiLi particles
each containing one of the enzymes of the cascade i.e one SiLi loaded with AChE,
one SiLi loaded with ChOx and one SiLi loaded with HRP only, the amount of
physical barriers for the substrate to diffuse through already triples thereby further
increasing the detection time of the ACh. The addition of Ch to ACh tremendously
improved the detection time as ChOx can metabolize Ch simultaneously as AChE
is degrading ACh to Ch. However this detection time isnt as quick as 3 enzymes
encapsulated in one SiLi particle.
4.7 Conclusion
This low cost method can be used to deliver at the sight of interest to detect
the rapidly degraded neurotransmitter. It will not only provide insights to the
neural connection but also bridge the small incidence to large scale pathological
symptom picked up in larger scanners. As we have demonstrated the ability to
encapsulate several enzymes with different size and charge to detect ACh. However
the rapidity in detection is lower compared to the free enzymes. However, the
ability to shield and activate the enzymes through ultrasound provides multitude
of advantages: The ability of the particles to be retained in the system till 7-8
days post injection suggests that the enzymes can be used for repeated detection
of ACh under different stimuli thereby providing insights to neural networks.
Three enzymes encapsulated in one particle performs better than 3 particles
each encapsulated with one enzyme, thereby hinting the diffusivity resistance of
the substrate/product through the silica. This method is analogous to kits that are
available commercially to detect ACh however, it can be scaled up to load multiple
independent enzymes detecting multiple neurotransmitters. This research echos
the sentiments of the brain mapping initiative and provides a powerful tool to aid
in optical detection of neuron activity.
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Chapter 5
Synthetic Hollow Enzyme Loaded
Silica Nanoparticle for ATP
Detection
5.1 Adenosine Tri-Phosphate (ATP)
Adenosine 5 Triphosphate, is a compound that captures the energy released
from catabolic processes and is able to transfer it to energy intensive reactions,
serving as a universal energy currency in the cells and therefore is available in
all living entities [143].ATP molecule consists of three different functionally dis-
tinct parts, The purine base ring- Adenine, Ribose sugar moeity and Triphosphate
tail. In Neurons, ATP levels are predominantly maintained through oxidative
phosphorylation in the mitochondria which generates ATP from ADP (Adenosine
Diphosphate) [144]. Newly synthesized ATP is produced and transported out of
the mitochondria via the oxidative phosphorylation with a steady state cytosolic
concentration of 3-10mM.
All living organisms use different mechanisms to monitors its functions in-
ternally and also with the environment to adapt, sustain and thrive in various
physiological conditions. These afferent mechanism share a common mechanism
which involves the release of ATP
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Figure 5.1: The electron transport chain in the cell is the site of oxidative phospho-
rylation. The NADH and succinate generated in the citric acid cycle are oxidized,
releasing energy to power the ATP synthase for generating ATP from ADP
5.2 Role of ATP
Unlike in many organs, Glucose is not the main source of energy in the brain.
Under certain circumstances, blood-derived energy substrates, like ketone bodies
and lactates also serve as energy sources at times of starvation and during peri-
ods of intensive physical activity [145].The brain has high energy requirements.
About 20% of the oxygen and 25% of the glucose consumed by the human body
are dedicated to cerebral functions, yet the brain represents only 2% of the total
body mass. Maintenance and restoration of ion gradients dissipated by signaling
processes such as postsynaptic and action potentials, as well as uptake and recy-
cling of neurotransmitters, are the main processes contributing to the high brain
energy needs [146].Among them, synaptic potentials, appear to represent the main
energetic cost related to maintenance of excitability especially in the glutamatergic
neurons [147].Under normal metabolic condition, The cytoplasmic concentration
of ATP is 10mmol/l [148]. This acts as the source for ATP for various reactions
like:
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• GTP and G protein activity
• Exocytosis
• Resting potential of the membrane maintained by Na+/K+ ATPase the
which consumes 60% of the ATP [146]
• Signal transduction and various protein kinases
Apart from the use in brain, many peripheral sensory excite different nerve
fibre through a common mechanishm that involves the activation of ionotropic cell
receptors (P2X) and metabotropic cell receptors (P2Y).
5.2.1 Current Techniques to Detect ATP
There are currently three methods for detecting exogenous ATP:
• Luciferase-Luciferin Assay[149]
• High Performance Liquid Chromotography (HPLC) (HPLC)[150]
• Radioactive labelling of the Purines [151]
• Patch-sniffing
However, The first two methods have a great sensitivity to the levels of exogeneous
ATP. The introduction of a foreign gene to produce luciferase by the cells would
limit the use of this assay based system to animal models. HPLC also has the
same sensitivity as the luciferase-luciferin assay system and it can also be used to
detect various other nucleotides and nucleosides in a single run. However the main
pitfall of this method of detection is that the detection isnt real time and would
require frequent and repeated injections to collect samples.
However studies have been conducted to study the ATP generation and release
in the pericellular spaces using electrodes. These electrodes are conjugated with
synthetic glycerol kinase and glycerol-3-phosphate oxidase. These methods require
complex signal processing techniques and have not been applied to physiological
measurements. Furthermore, this technique can also measure ambient change in
glucose concentration and hence cannot be applied on biological tissue[152].
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5.2.2 ATP Release in cells
There are four general mechanisms by which intracellular ATP can be re-
leased into extracellular spaces[153][154]. [155].
• The intracellular concentration of ATP in cytoplasm can range from 3-5mM,
non specific lysis of healthy cells by trauma (physical and chemical) can be
contribute to release in extracellular ATP.
• Release through compartmentalized vesicles formed during regulated and un-
regulated exocytosis where ATP is packaged along with the package present
the vesicles like in neurons, endocrine etc.
• Eﬄux of ATP in cytoplasm via membrane transport proteins
• Release through cell membrane rupture caused due to hypoxia, inflammation,
drug metabolism and apoptosis.
ATP is released from several tissues and organs. In 1929, Albert Szent-Gyorgyi and
Alan Drury concluded that adenylic acid is the molecule in muscle extract that
caused contraction of the smooth muscles. Boyd and Forrester studied several
substances that were released by muscle, which when applied to frog heart would
increase their heart rate which was later found to contain ATP [156]. Exercise
[157][158], hypoxia [159], fluid shear [160] and various ligands [161] lead to release
in ATP in the bloodstream in humans but the specific mechanism of release is still
unclear. As we know, any biological function in the human cell requires energy
including neurons. The activation of Na+/K+ channels is mediated by the hydrol-
ysis of ATP to ADP (Adenosine Diphosphate). Because ATP is a very essential
substrate for metabolism, the release of ATP is met with some consequences in-
side the cells. However, If one assumes that the steady-state extracellular ATP is
approximately 10 nM under basal conditions and intracellular ATP is 10 mM, the
gradient for ATP secretion is approximately 106 -fold. This gradient is 100-fold
greater, yet opposite to, the gradient for calcium entry into cells. Thus only 1% of
the intracellular ATP is released to activate almost all the receptors. Hence, the
release of ATP is accomplished without any affect in the cellular metabolism [162].
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Administration of ATP to various regions of the brain produced biochemical
or electro-physiological changes like an injection of ATP into the lateral ventricle in
cats resulted in muscular weakness, ataxia and put the animal to sleep[163]. ATP
is also a neurotransmitter as they were released during antidromic stimulation of
sensory neurons supplying the artery of rabbit ears and eyes [164][165]. The half life
of ATP once released into the extra cellular matrix is very low. This is because ATP
is degraded by ectoenzymes localized in surrounding tissues. Thus the extracellular
level of ATP measured in the outside the tissue reflects not only the rate of release
of ATP, but also the rate of breakdown of released ATP, which is dependent on the
activity of the surface located ectoATPases in a given tissue. Chemical drugs and
treatment which affect the release of ATP may also affect inactivation of ATP so
that measurements on the release and degradation of extracellular ATP provides a
better quantification for the release process [166]. Apart from ATP being released
by cells that are dying [167], recent research suggests that ATP can also act as
a chemical messenger between the glial cells and neurons [168]. ATP can also be
released in the neuromuscular junctions and is considered as a Neurotransmitter.
Nerve terminal ATP is generated from ADP during glycolysis , citric acid cycle and
mostly by oxidative phosphorylation. Storage of synthesized ATP is in different
types of synaptic vesicles and also in cytoplasm. They are sometimes co-packages
with many other neurotransmitters like the ACh and noradrenaline in purinergic
neurons [143].
Several factors complicates the detection and measurement of physiological
availability of extracellular ATP that are released. The ubiquiotus nature of ATP
makes it even more difficult to determine the source of ATP being released. Fur-
thermore the ecto-nucleotidases rapidly hydrolyse ATP thereby making it harder
to detect the ATP released[169][170]. Inspite of the hydrolysis, the rapid motion
of blood and fluid diffuses the ATP thereby diluting the concentration of the ATP.
Due to this dynamic nature, most measurement techniques employed to detect
ATP in the bulk fluid would vastly underestimate the amount of ATP released,
this may be particularly true in cells that do not have direct contact with flowing
fluids and blood like the neurons. Hence, the ATP released is enough to activate
cells locally but not in the bulk solutions[171][172].
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Since firefly luciferase can be used to detect pico molar and nano molar con-
centration of ATP through luminescence, it is the most widely used technique
to detect ATP[173][174][175]. However majority of the measurement of ATP has
been through the analysis of the bulk solutions after the release of ATP, the results
derived have results in disagreement among many researchers with contradicting
results[174]. In principle, the sensitivity of luciferase as a sensor of ATP release
into localized or restricted extracellular spaces can be improved dramatically with-
out causing any immune reaction against luciferase in live animals by the use of
nanoparticles.
5.3 LuciSHELS
5.4 Materials
200 nm diameter NIST (National Institute of Standards and Technology)
polystrene (PS) beads were purchased from Polysciences Inc, Warminster, PA.
60nm PS beads functionalized with carboxyl group were purchased from Bangs
Laboratories inc, Fishers, In. Luciferase from from Photinus pyralis, D-Luciferin,
(3-Aminopropyl) trimethoxysilane (APTMS), Tetramethyl orthosilicate (TMOS)
were purchased from Sigma Aldrich, St Louis, MO. 190 proof ethyl alcohol was
purchased from FisherScientific, Waltham, MA. Phosphate Buffer Saline (PBS)
was purchased from Hyclone Laboratories Inc,Logan, UT. Poly-l-lysine (PLL) ,
5.5 Method
5.5.1 Synthesis of LuciSHELS
The hollow silica particle was synthesized using the modified version as de-
scribed by Ortac [28]. In brief, 60 ul of larger PS bead ( 200nm)-template, was
mixed with 40ul of smaller PS beads ( 60nm)- mask for 15 mins at high speed.
This results with the PS masks electrostatically bonded to the template thereby
resulting in a spike ball like structure. 1ml of 190 proof ethanol was added drop
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wise to the template-mask mixture. 1ul of APTMS and 2ul of TMOS was added
sequentially to the ethanol mixture and mixed for 4 hours in room temperature.
The spike ball like nanostructure forms the base over which the silica is templated.
The 200nm PS beads serves as a template over which the silica begins to grow. The
rate of the silica precipitation on the template can be controlled by the amount
of water and APTMS added. The silica precipitation reaction was stopped by
washing the sample in centrifuge at 14 g for 10 mins. The pellet was resuspended
in 1ml of ethanol and this process is repeated for 3 times. After the final wash, the
pellet was re-suspended to 60 ul of ethanol. The solution is calcined in a ceramic
crucible at 475oC overnight in a laboratory grade convection oven.
The calcined product was redispered in ethanol from the crucible and washed
into DI water. Until the last centrifuge process, where the pellet is not dispersed
in water but in 60ul of 50mg/ml of luciferase solution in PBS. The said mixture is
mixed under vortex overnight in 4oC. This ensures that the enzyme has enough time
to diffuse into the hollow silica nanoparticles. The enzyme-nanoparticle solution
can be sonicated in an ice bath for 60 seconds with 1 sec on and 1 sec off pulse
under 20 % amplitude. (Refer figure5.2B)
After overnight mixing, the enzyme-nanoparticle complex is mixed with 5ul
of 10% w/v PLL for 10 minutes. This produces a uniform coating of the long chain
polymer- PLL to cover the mesoporous holes through electrostatic attraction (PLL
is positively charged and silica is negatively charged). This prevents the enzymes to
leak out temporarily from the nanoparticle (Refer figure5.2C). To ensure that the
enzyme is completely sealed in the nanoparticle, the enzyme-nanoparticle mixture
is diluted with 1 ml of PBS and mixed with 25 ul of silisic acid overnight at 4oC
. Silisic acid is produced by mixing 100ul of 1mM of HCl with 14.8 ul of TMOS.
Silisic acid is highly reactive and generates silicon hydroxide hydrogel layer on the
nanoparticle which is preferentially grown on the PLL, which covers the surface of
the nanoparticle (Refer figure5.2D). Due to the high reactivity of the silicic acid,
this solution has to be prepared right before the addition to the particles.
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5.5.2 Characterization of the LuciSHELS
The size and surface charge of the liposomes were characterized using Zeta-
sizer Nano fromMalvern Instruments,Malvern, UK. The size was also characterized
using electron microscope images using the Helios NanoLab DualBeam from FEI.
The luminescence activity of the enzyme was optically detected using Infinite 200
PRO series from Tecan, Mannerdorf, SUI.
5.5.3 Enzyme Encapsulation Efficiency Determination
The enzyme encapsulation efficiency was conducted with Luciferase-luciferin
luminescence assay. A standard curve was conducted with different concentra-
tion of luciferase along with 0.01mg/ml of D-luciferin and 1µM ATP dissolved in
deionized water (DI water).
5.5.4 Luciferin ATP assay for the Measurement of Lu-
ciferase Activity
The LuciSHELS and unencapsulated luciferase activity was measured using
luminescence assay at 512 nm. The sample was incubated with 0.01mg/ml of D-
luciferin at 37oC while mixing for 5 mins prior to the addition of 50µl of ATP
(concentrations ranging from 1mM to 1pM).
5.5.5 Luminescence Detection in vitro
Far-field optical signals were collected using an upright optical microscope
equipped with a 50x (Nikon, NA 0.55) objective and an EMCCD camera (Ixon,
Andor Technology). The particles were injected in certain pre-determined locations
on the PDMS mould. 100µl of 0.1mg/ml of luciferin was added prior to addition
of ATP. 100µl of ATP with different concentrations were prepared and added
dropwise at the end of the PDMS mould away from the predetermined locations
of LuciSHELS.
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5.6 Results
The size of SHELS through DLS was determined to be around 240 nm and
the surface charge to be -26mV before encapsulation with luciferase. The size of
SHELS was found to be 215nm using scanning electron microscopy (SEM) before
sealing with luciferase. However there is a huge change in the charge of the SHELS
once it has been sealed using a sol-gel layer from the bare SHELS. The charge of
the the sealed particles was determined to be -18mV.
Different methods to coat the surface have been studied to influence the ac-
tivity of the enzyme inside the LuciSHES. Several other surface coatings were also
tested in addition to silicic acid. APTMS was added to provide another uniform
layer of Si-amines on the surface thereby making the surface more cationic com-
pared to just the anionic silicic acid. However, the addition on PEG to the sol-gel
layer makes the surface change of the SHELS more neutral. As seen from the
figure5.3, addition of PEG does show a higher detectable signal compared to other
coating at the same ATP concentrations. This is very dramatic at lower ATP con-
centrations. All the LuciSHELs used in this experiment were loaded with 50mg/ml
of luciferase. The figure5.3 shows that addition of PEG on the surface is important
in improving the signal at lower ATP concentrations. Similar experiments were
conducted to tested the luminescence at 1nM of ATP of LuciSHELS with and
without the addition of PEG, with two different enzyme concentrations: 30mg/ml
and 1mg/ml. As inferred from the figure5.4, the luminescence of all the samples
coated with PEG performed better to the ones that did not undergo PEGlation.
Especially, PEGlated version of SHELS loaded with 1mg/ml of luciferase did per-
form better compared to its counterpart (non peglation), which shows almost no
detectable signal. LuciSHELS activity was measured along with the unencapsu-
lated luciferase at different concentration of ATP to determine any changes in the
enzyme kinetics due to encapsulation in the SHELS. Figure5.5 shows that the en-
zyme kinetics between free and LuciSHELS were found to follow the similar trend.
To detect ATP in a dynamic solution and to capture the flash and glow lumines-
cence. LuciSHELS loaded with 80mg/ml of luciferase was embedded in a clear
PDMS mould at different locations across the surface. the whole mould was filled
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with 0.1mg/ml of D-luciferin. Figure5.6 shows the luminescence immediately and
after 10 seconds after the addition of 500µl of 1nM ATP. The luminescence signal
clearly appears to be decaying with time. However, the figure5.7 shows lumines-
cence measured at 10 seconds after the addition of 500µl of 1nM ATP at 2 different
locations of SHELS, L1-a refers to the position closer to the site of the addition of
ATP while L2 is further away from L1-a while L1 is the same location as of L1-a
taken prior to the addition of ATP. This shows the path of ATP diffusion across a
flat PDMS mould.
5.7 Discussion
Luciferase encapsulated SHELS provide a platform for detecting ATP in site
specific regions like the brain and cardiomyocytes. The charge of the SHELS prior
to the coating with PLL forms the a charge based anionic template due to the
presence of silica. The attraction of PLL onto the silica is purely electrostatic and
the shift in the surface charge of the particles shifts from anionic to cationic do-
main. PLL is cationic due to the presence of primary amine groups in a long chain
polymer [176]. Condensation of silicic acids leads to the formation of long chain
polymeric silicic acid in aqueous solutions which preferentially forms over the PLL
electrostatically. Sol-gel silica tends to be less anionic compared to calcinated silica
which is what is infered from the zeta measurements of LuciSHELS particles. As
seen from the figure??, the surface charge of the SHELS does play an important
role in transport of the small molecules across the nanopores formed during the
solgel process. D-Luciferin and ATP are both anionic [177] molecules which would
be repelled by the anionic silica coating. The APTMS coating would preferentially
change the surface charge from negative to positive but has little to no improve-
ment in the luminescence as seen in figure5.3. This may be because the substrates
might be attracted to the particles but retained at the surface rather than being
metabolized with luciferase. However, Neutralizing the surface charge with PEG
provides little to no hindrance in diffusion of the substrate across the nanoparti-
cles thereby being consumed by luciferase which can be inferred by the increase
in luminescence even at lower concentrations of ATP. Figure5.3shows the effect of
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different surface on the diffusivity of the substrate and interact with 50mg/ml of
luciferase loaded in SHELS. Further to see the effect of different enzyme loading
concentration with SHELS coated with PEG. Figure5.4 shows a drastic increase in
the detection signal at lower concentrations of luciferase encapsulated in SHELS
coated with PEG. At physiological ATP concentration of 1nM, PEG coated Lu-
ciSHELS loaded with 1mg/ml of enzyme provides roughly 100 folds increase in
activity compared to its no PEG counterpart. In Addition to the PEG, activity of
free luciferase and LuciSHELS at same ATP concentration provide similar lumi-
nescence readout. This shows that the enzyme, even though encapsulated inside a
nanoparticle behaves like the free enzyme and it further reaffirms that no chemical
or physical modification was performed with the enzyme during encapsulation that
lead to any change in the activity kinetics.
Figure5.6 shows the luminescene decay with time. The catalysis of the lu-
ciferin and ATP is instantaneous and rapid, hence can be used for detecting nerve
impulse and electrical impulses that releases ATP like in cardiomyocytes. How-
ever, the diffusion of ATP is uncontrolled in the body and can diffuse randomly,
figure5.7 shows the luminescene decay measured at the same time between two
locations which are embedded with SHELS. The location L2 which is further away
from L1-a shows a lower intensity while the L1-a shows higher intensity due to
the close proximity of the location of the injection of 1nM ATP. The incidence
captured in the figure5.7 indicates that any ATP that diffuses through the fluid
can still be picked up and metabolised. This provides a foundation to conduct
further experiments on tracking the nerve impulse along a specific nerve pathway,
thereby a strong tool for mapping the brain activity.
5.8 Conclusion
We have demonstrated a hollow silica nanoparticle loaded with luciferase to
detect ATP in the presence of luciferin. The synthesis and fabrication indicated
that different concentration of luciferase can be loaded in the particle to improve
the detection. We have also demonstrated that the surface charge of the nanopar-
ticle plays a very vital role in detecting ATP. Neutrally charged nanoparticles seem
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to provide better dynamic range for detection even at lower concentration of ATP.
To simulate the ATP diffusion in real system, we have employed the use of a PDMS
which indicates that the luciSHELS are able to detect the ATP at different time
intervals. The present formulation allows the nanoparticles to localize at the site
of injection, this would be desirable in detecting ATP levels both in neurons and
in cardiomyocytes.
However, the formulation does have its pitfalls. The enzyme used for the
detection of luminescence doesnt not perform well at lower concentrations of ATP.
This might mandate the research to synthesize synthetic luciferase with higher
light units yield per ATP hydrolysed. Secondly, Apart from the high enzyme
loading capabilities of SHELS. The fabrication process is extremely sensitive to the
composition of the template and the mask. Since this nanoparticle is completely
synthesized from silica, there are possibilities to toxicities at higher dosage.
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Figure 5.2: Schematic representation of the synthesis of SHELS. (A) Hollow silica
nanoparticle (B)High concentration enzyme loading through diffusion. (C) PLL-
Cationic polymer coated hollow silica nanoparticles (D)Hollow silica nanoparticles
sealed with another sol-gel layer through silicic acid
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Figure 5.3: Luciferase luminescence at different ATP concentration with different
surface coating. Si: Just Silicic Acid. APTMS: Silicic acid and APTMS. PEG:
Silicic acid and PEG-2000
Figure 5.4: Luminescence of SHELS coated with and without PEG and loaded
with different enzyme concentration,1mg/ml and 30mg/ml at 1nM of ATP and
0.1mg/ml of D-luciferin
67
Figure 5.5: Comparison of enzyme kinetic study between the luciferase and Lu-
ciSHELS performed at different concentrations of ATP at 0.1mg/ml of D-Luciferin
Figure 5.6: Luminescence measured at a single location after 1 second and 10
seconds after the addition of 1nM ATP
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Figure 5.7: Luminescence measured at a multiple location at 10 seconds after the
addition of 1nM ATP,L1: Location before the addition of ATP. L1-a: Area closer
to ATP addition. L2: Location Further away laterally to L1-a.
Chapter 6
Conclusion and Final Notes
The application of SiLi are multi-faceted. The ability of the particle to
encapsulate enzyme irrespective of the size and charge with minimal to none loss
in activity and stability proves to be a promising platform in delivering bio active
molecules in the body. Not only the biomolecules (here enzymes) retain similar
activity to the free enzymes, it also provides protection to the bio molecules against
specific and non specific neutralization from the immune system.
The fabrication procedure is general and should be applicable to many other
materials. As shown previous in figures2.9 and 4.6, SiLi can be made of differ-
ent materials and for variety of different applications. With the addition of the
inorganic layer (like silica and CaP) on the liposomes not only protects it from
the immune system but it also opens up opportunities to functionalize the surface
with specific targeting agents like EGFR, VegF, bungarotoxin which improves the
therapeutic and diagnostic efficacy in vivo.
Not only can the nanoparticles be targeted upon the addition on several tar-
geting moeities, the activity of the enzyme loaded can be also be manipulated upon
the application of the ultrasound. The lipids in the liposomes are closely bound
to prevent any interaction of the enzymes with the outside environment, how-
ever upon the exposure of ultrasound, the lipids tend to manipulate and perforate
thereby exposing the enzyme to the substrate. Since the application of ultrasound
doesnt affect the silica coating, the enzyme can be activated without hampering
its activity and additionally also providing protection against any specific and non
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specific immune reactions.
For the application in medicine, there are still many aspects of the SiLi that
needs to be studied. The use of HiFU needs to be tested and quantified on the
enzymes activity and stability loaded in SiLi. The toxicity and quantification of
the immune response on SiLi will need further study.
More studies need to conducted to determine the surface functionalization of
the SiLi to improve the circulation half life, thereby eliminating the need for chem-
ical modification of the enzyme payload. The use of CaP as a secondary coating
instead of silica is promising and needs to explored. However with the addition
of the secondary layer - Si, The CeLi do not maintain the structural integrity and
hence collapse. So further stduies are required to explore the possibilities of using
different lipids like sphingolipids, DOPE, Soy PC or DSPC etc. The use of polymer
like PLGA, PCL, Dextran, can also be employed to further strengthen the lipid
structure without compromising its echogenic properties. However in these con-
ditions, the enzymes in SiLi has controlled access to substrate which makes it an
excellent choice for treating brain diseases, cancer and pregnancy related problems.
The of SiLi is not only limited to protein carrier it can also be employed to
carry small molecules which can be used for imaging as well as for therapeutics.
One such usage would be to encapsulate analgesics in these particles which would
be very useful for trigger release of analgesics after an open wound surgery.
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